Blincyto 35 mcg lyophilized powder for injection Images
Generic Name: blinatumomab
This medication has been identified as Blincyto 35 mcg lyophilized powder for injection. It is supplied by Amgen Inc.
Blincyto is used in the treatment of Acute Lymphoblastic Leukemia and belongs to the drug class CD19 monoclonal antibodies. Risk cannot be ruled out during pregnancy. Blincyto 35 mcg lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Blincyto
- Generic Name
- blinatumomab
- Strength
- 35 mcg lyophilized powder for injection
- Availability
- Prescription only
- Drug Class
- CD19 monoclonal antibodies
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Amgen Inc.
- National Drug Code (NDC)
- 55513-0160
More about Blincyto (blinatumomab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD19 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
